CPT code 87487 represents a molecular diagnostic laboratory test that quantifies infection with Chlamydia pneumoniae using a nucleic acid probe technique. This code matters nationally because Chlamydia pneumoniae is a common respiratory pathogen with variable clinical severity across age groups; accurate laboratory quantification supports diagnosis, epidemiologic surveillance, and appropriate clinical management pathways.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers typically classify and reimburse molecular infectious disease testing, and highlights considerations relevant to lab services billing, documentation, and site-of-service impacts.

Readers will learn the clinical context for use of CPT code 87487, the typical settings where the test is performed (clinical and hospital laboratories), and the service type (molecular diagnostic assay for infectious disease). The piece provides benchmarks and policy context relevant to laboratory molecular testing reimbursement and coding practice, summarizes common modifier usage where applicable, and identifies areas where payers commonly require documentation or prior authorization. Data not available in the input is noted where applicable.